Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adriamycin + cisplatinum + etoposide
- Development stage
- Unknown
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This combination chemotherapy regimen consists of three anticancer drugs: adriamycin (doxorubicin), cisplatin (cisplatinum), and etoposide. It represents a multi-agent approach to cancer treatment, combining drugs with different mechanisms of action to enhance efficacy against cancer cells while managing the overall toxicity profile.
- Other names
- doxorubicin + cisplatinum + etoposideAdriamycin, Platinum, VP-16
02
Targets
Genomic DNA basesTOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on adriamycin + cisplatinum + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adriamycin + cisplatinum + etoposide.